iShares Evolved U.S. Innovative Healthcare ETF (IEIH)

Key Metrics

TER 18.00% per year

Distribution policy Accumulating

Fund size USD 37 M

Inception date March 21, 2018

Holdings 269

Fund currency USD

Fund domicile US

Provider iShares

Historical Return

Last updated: Jun 15, 2026

1 Year N/A

3 Years (avg.) N/A

5 Years (avg.) -0.2%

Risk & Analysis Metrics

Last updated: Jun 15, 2026

Volatility

N/A 1 Year

N/A 3 Years

10.64% 5 Years

17.12% 10 Years

Max Drawdown

N/A 1 Year

N/A 3 Years

-19.94% 5 Years

-22.38% 10 Years

Sharpe Ratio

N/A 1 Year

N/A 3 Years

-0.38 5 Years

0.15 10 Years

Return Triangle (Heatmap)

Last updated: Jun 15, 2026

	2018	2019	2020	2021	2022
2018	-2.6%	7.5%	10.2%	10.2%	7.4%
2019		18.6%	17.2%	14.9%	10.0%
2020			15.8%	13.1%	7.3%
2021				10.5%	3.3%
2022					-3.4%

Distributions

*by ETF Portfolio Weight Last updated: Jun 15, 2026

Profit Margin Distribution

< 0%

18%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

10%

1y 3y N/A N/A

10 - 15%

13%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

27%

1y 3y N/A N/A

30 - 40%

21%

1y 3y N/A N/A

> 40%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

18%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

1y 3y N/A N/A

15 - 20

14%

1y 3y N/A N/A

20 - 25

11%

1y 3y N/A N/A

25 - 35

27%

1y 3y N/A N/A

35 - 50

11%

1y 3y N/A N/A

> 50

11%

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

1.4%

1y 3y N/A N/A

Small Cap

5.3%

1y 3y N/A N/A

Mid Cap

7.1%

1y 3y N/A N/A

Large Cap

52.3%

1y 3y N/A N/A

Mega Cap

33.9%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Jun 21, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$252B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	1.38%	2.03%
Beta Indicates the relationship between the price performance of a share and the market.	0.49	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	35.48	28.29
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-31.73	-
Profitable Companies	82%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	33.42	14.56
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	7.42	8.28
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	10.7	10.72

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	15.74	21.15
Enterprise Value to Revenue Enterprise value divided by revenue	7.79	8.72
Total Debt to Enterprise Value Total debt divided by enterprise value	0.11	0.05
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	1.04	0.33
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	8.26%	-6.18%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-9.4%	-117.9%
Return on Equity Equity divided by market cap.	24.38%	1.23%
Return on Assets Indicates a company's profitability in relation to its total assets.	4.36%	3.29%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	9.87%	3.31%

Sectors

Manufacturing	84.5%
Professional, Scientific, and Technical Services	3.2%
Health Technology	0.7%
Health Care and Social Assistance	0.7%
Finance and Insurance	0.4%
Wholesale Trade	0.2%
Information	0.0%
Healthcare	0.0%
Other	10.3%

Countries

Other	50.4%
United States	49.6%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Johnson & Johnson

JNJ - Manufacturing

Market Cap $549.78B

P/E Ratio 26.5

Dividends 2.3%

Total Investment $3.77M

Weight 10.24%

Loading details…

Lilly(Eli) & Co

LLY - Manufacturing

Market Cap $1.03T

P/E Ratio 38.9

Dividends 0.6%

Total Investment $2.78M

Weight 7.55%

Loading details…

Abbvie Inc

ABBV - Manufacturing

Market Cap $382.74B

P/E Ratio 106.2

Dividends 3.1%

Total Investment $2.24M

Weight 6.08%

Loading details…

Merck & Co Inc

MRK - Manufacturing

Market Cap $281.24B

P/E Ratio 31.5

Dividends 3.0%

Total Investment $2.12M

Weight 5.77%

Loading details…

Bristol-Myers Squibb Co.

BMY - Manufacturing

Market Cap $110.27B

P/E Ratio 15.2

Dividends 4.6%

Total Investment $1.97M

Weight 5.36%

Loading details…

Vertex Pharmaceuticals, Inc.

VRTX - Manufacturing

Market Cap $114.63B

P/E Ratio 26.5

Dividends 0.0%

Total Investment $1.89M

Weight 5.13%

Loading details…

Moderna Inc

MRNA - Manufacturing

Market Cap $25.38B

P/E Ratio -7.9

Dividends 0.0%

Total Investment $1.66M

Weight 4.50%

Loading details…

AMGEN Inc.

AMGN - Manufacturing

Market Cap $182.21B

P/E Ratio 23.3

Dividends 2.9%

Total Investment $1.61M

Weight 4.38%

Loading details…

Gilead Sciences, Inc.

GILD - Manufacturing

Market Cap $153.66B

P/E Ratio 16.7

Dividends 2.6%

Total Investment $1.48M

Weight 4.01%

Loading details…

Regeneron Pharmaceuticals, Inc.

REGN - Manufacturing

Market Cap $62.84B

P/E Ratio 14.3

Dividends 0.6%

Total Investment $1.46M

Weight 3.96%

Loading details…

Zoetis Inc - Ordinary Shares - Class A

ZTS - Manufacturing

Market Cap $33B

P/E Ratio 12.6

Dividends 2.6%

Total Investment $912.57K

Weight 2.48%

Loading details…

Biogen Inc

BIIB - Manufacturing

Market Cap $29.02B

P/E Ratio 21.0

Dividends 0.0%

Total Investment $843.04K

Weight 2.29%

Loading details…

Seagen Inc

SGEN - Manufacturing

Market Cap $43.15B

P/E Ratio -69.2

Dividends 0.0%

Total Investment $672.05K

Weight 1.83%

Loading details…

Alnylam Pharmaceuticals Inc

ALNY - Manufacturing

Market Cap $37.13B

P/E Ratio 63.8

Dividends 0.0%

Total Investment $541.74K

Weight 1.47%

Loading details…

Horizon Therapeutics Plc

HZNP - Manufacturing

Market Cap $26.6B

P/E Ratio 51.1

Dividends 0.0%

Total Investment $477.91K

Weight 1.30%

Loading details…

Biomarin Pharmaceutical Inc. - Registered Shares

BMRN - Manufacturing

Market Cap $10.57B

P/E Ratio 39.1

Dividends 0.0%

Total Investment $463.38K

Weight 1.26%

Loading details…

Incyte Corp.

INCY - Professional, Scientific, and Technical Services

Market Cap $19.62B

P/E Ratio 13.7

Dividends 0.0%

Total Investment $399.66K

Weight 1.09%

Loading details…

Royalty Pharma plc - Ordinary Shares - Class A

RPRX - Manufacturing

Market Cap $22.78B

P/E Ratio 27.6

Dividends 1.7%

Total Investment $283.99K

Weight 0.77%

Loading details…

Astrazeneca plc - ADR

AZN - Health Technology

Market Cap $294.4B

P/E Ratio 26.0

Dividends 1.8%

Total Investment $256.97K

Weight 0.70%

Loading details…

United Therapeutics Corp

UTHR - Manufacturing

Market Cap $22.78B

P/E Ratio 18.1

Dividends 0.0%

Total Investment $238.93K

Weight 0.65%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow

The Portfolio That Gets You a Waterfront Condo in Miami Beach

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Johnson & Johnson

Johnson & Johnson

Lilly(Eli) & Co

Lilly(Eli) & Co

Abbvie Inc

Abbvie Inc

Merck & Co Inc

Merck & Co Inc

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc.

Moderna Inc

Moderna Inc

AMGEN Inc.

AMGEN Inc.

Gilead Sciences, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Zoetis Inc - Ordinary Shares - Class A

Zoetis Inc - Ordinary Shares - Class A

Biogen Inc

Biogen Inc

Seagen Inc

Seagen Inc

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Horizon Therapeutics Plc

Horizon Therapeutics Plc

Biomarin Pharmaceutical Inc. - Registered Shares

Biomarin Pharmaceutical Inc. - Registered Shares

Incyte Corp.

Incyte Corp.

Royalty Pharma plc - Ordinary Shares - Class A

Royalty Pharma plc - Ordinary Shares - Class A

Astrazeneca plc - ADR

Astrazeneca plc - ADR

United Therapeutics Corp

United Therapeutics Corp

Cookie Settings